Daily Brief Health Care: Sharecare , Sumitomo Pharma, AS ONE Corporation, Oryzon Genomics, Addex Therapeutics, Symbio Pharmaceuticals and more

• Sharecare is a data-driven healthcare platform with three segments and access to a large amount of data from claims and eligibility information for 13 million covered lives
• The company has a market cap of $243 million and generates around $445 million in revenue, with an adjusted EBITDA breakeven
• Sharecare has a strong cash position, no debt, and a promising outlook for their life sciences segment, making it a potentially valuable investment opportunity

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• Sumitomo Pharma (4506 JP) reported double-digit revenue growth in Q1FY25, driven by North America. Operating loss narrowed. Net profit stood at ¥16B in Q1FY25 (Q1FY24 net loss: ¥39B).
• Robust performance of key products, gross margin expansion, achievement of sizable benefits from the North America business restructure, and streamlining R&D initiatives are the key positives in Q1FY25 result.
• Sumitomo is expected to revise FY25 guidance during H1FY25 result announcement. Better-than-expected performance from key drugs as well as favorable Fx should lead to upward revision of revenue guidance.

• Q1 FY03/25 sales were JPY24.2bn (+11.2% YoY), operating profit JPY2.7bn (+11.3% YoY), and net income JPY2.0bn (+10.9% YoY).
• Research and Industrial Instruments sales JPY19.7bn (+10.9% YoY), Scientific sales JPY14.6bn (+10.0% YoY), Industrial sales JPY5.1bn (+13.6% YoY).
• E-commerce sales JPY8.0bn (+23.3% YoY), overseas business sales JPY1.2bn (+4.6% YoY), China sales down 7.3% YoY.

Oryzon’s Q224 results summarised an active quarter for its clinical pipeline, with multiple milestones expected in H224. Central to the H224 momentum will be the upcoming FDA end-of-Phase II (EoP2) meeting for vafidemstat in BPD, for which a positive outcome would provide impetus to subsequent plans. Interim data from FRIDA (iadademstat in AML) was encouraging, and with several additional combination trials planned, the second half of the year will continue to be highly active. Operating results threw no surprises, with R&D expenses remaining soft (€2.2m in Q224) following the PORTICO trial completion in late 2023. The period-end gross cash balance of €10.1m was supported by another €4m drawdown from the November 2023 convertible debt facility and should support operations into FY25. As we make minor revisions to our estimates, our valuation adjusts to €774.7m versus €748.8m previously. Our per share valuation remains unchanged (€12.1) on a higher post-conversion share count.

• Addex is a stub allowing investors to invest in Neurosterix at a lower valuation
• Neurosterix, backed by blue-chip VC firms, focuses on targeting muscarinic receptors for psychiatric disorders
• Addex transferred assets to Neurosterix in exchange for equity, including an M4 PAM and an mGlu7R NAM

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• Sales decreased by 59.6% YoY to JPY1.3bn, with a gross profit of JPY996mn and a gross profit margin of 77.6%.
• Operating loss was JPY1.7bn, recurring loss JPY1.5bn, and net loss attributable to owners of the parent JPY1.5bn.
• SG&A expenses were JPY2.7bn (+7.6% YoY), with R&D expenses amounting to JPY1.5bn (+27.2% YoY).